Search

Iovance Biotherapeutics Inc

Закрыт

СекторЗдравоохранение

8.05 -2.78

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

7.78

Макс.

8.35

Ключевые показатели

By Trading Economics

Доход

32M

-47M

Продажи

28M

99M

Прибыль на акцию

-0.11

Рентабельность продаж

-47.642

Сотрудники

975

EBITDA

32M

-39M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+5.07% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.3B

3.2B

Предыдущая цена открытия

10.83

Предыдущая цена закрытия

8.05

Новостные настроения

By Acuity

50%

50%

147 / 340 Рейтинг в Healthcare

Iovance Biotherapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

21 авг. 2026 г., 20:02 UTC

Iovance Biotherapeutics is lower in Friday's session, with no specific news identified. The broader market also remains down significantly since Thursday's close.

20 авг. 2026 г., 23:06 UTC

News

Iovance Biotherapeutics reached a 52-week high after UBS raised its target price to $7, noting strong second-quarter sales of $91 million.

19 авг. 2026 г., 23:16 UTC

News
Social Media

Iovance Biotherapeutics shares reached a new 52-week high amid positive melanoma treatment sector sentiment and an anticipated revenue guidance increase.

18 авг. 2026 г., 23:06 UTC

Iovance Biotherapeutics shares were roughly flat in after-market hours. The broader market faced pressure from rising bond yields and increased oil prices.

17 авг. 2026 г., 19:36 UTC

Social Media

Iovance Biotherapeutics reaches a new 52-week high above $7 amid positive results from the IOV-LUN-202 trial for metastatic NSCLC.

14 авг. 2026 г., 23:26 UTC

Social Media

Iovance Biotherapeutics Inc. gains in after-market trading, reaching a 52-week high above $7 amid positive sentiment for IOV-LUN-202 and upcoming updates.

13 авг. 2026 г., 19:21 UTC

Iovance Biotherapeutics Inc shares are lower today, reaching a midday low after earlier gains. No specific news was identified to explain the decline.

12 авг. 2026 г., 19:16 UTC

Social Media

Iovance Biotherapeutics Inc shares rise amid positive social media discussions and analyst projections of over $400 million in revenue this year.

11 авг. 2026 г., 23:46 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours amid volatility. No specific news was identified to explain the price movement.

10 авг. 2026 г., 23:56 UTC

News

Iovance Biotherapeutics reported second-quarter revenue of $99.3 million, a 66% increase, contributing to a rise in shares during after-market hours.

7 авг. 2026 г., 20:03 UTC

News
Social Media

Iovance Biotherapeutics rises as Barclays and Citizens raise price targets amid positive sentiment and high trading volume.

6 авг. 2026 г., 20:03 UTC

Social Media
News

Iovance Biotherapeutics reported record Q2 revenue of $99.3 million, exceeding estimates. The stock is higher amid strong demand and FDA Fast Track Designation for SAR-201.

5 авг. 2026 г., 23:16 UTC

Iovance Biotherapeutics shares are higher in after-market trading, reflecting broader market strength amid falling crude oil prices and strong corporate earnings.

4 авг. 2026 г., 19:51 UTC

Iovance Biotherapeutics is rising amid broader market strength from falling crude oil prices and positive economic data, despite lingering inflation concerns.

3 авг. 2026 г., 19:51 UTC

Iovance Biotherapeutics shares are higher today, rebounding from an earlier low. The stock has advanced since Friday, amid positive market sentiment.

31 июл. 2026 г., 23:41 UTC

Iovance Biotherapeutics shares are higher in after-market trading, maintaining gains since Friday's close amid broader market volatility following a decline in Apple shares.

30 июл. 2026 г., 23:51 UTC

Iovance Biotherapeutics shares are lower in after-market trading, reflecting ongoing weakness and pulling back from a brief session high earlier.

29 июл. 2026 г., 15:16 UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a trend of declines over the past six sessions with no specific news identified.

28 июл. 2026 г., 23:56 UTC

Iovance Biotherapeutics shares declined in after-market trading, continuing a trend of lower finishes over the past five sessions. No specific news was identified.

27 июл. 2026 г., 19:36 UTC

Social Media

Iovance Biotherapeutics is lower today, continuing a trend of declines over four consecutive trading days. Earlier, shares rebounded from a session low.

24 июл. 2026 г., 19:12 UTC

Iovance Biotherapeutics Inc shares are lower today, continuing a downward trend amid broader market volatility influenced by falling oil prices and geopolitical tensions.

22 июл. 2026 г., 23:11 UTC

Iovance Biotherapeutics shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector. The stock remains near its one-month trading range high.

21 июл. 2026 г., 19:46 UTC

Social Media

Iovance Biotherapeutics shares are higher amid positive social media sentiment and favorable earnings reports from peers, including General Motors and Novartis.

20 июл. 2026 г., 19:16 UTC

Social Media

Iovance Biotherapeutics Inc shares are higher today, with significant trading volume reaching 23.48 million. The stock has fluctuated between 4.44 and 5.07 during the session.

Сравнение c конкурентами

Изменение цены

Iovance Biotherapeutics Inc Прогноз

Целевая цена

By TipRanks

5.07% рост

Прогноз на 12 месяцев

Средняя 8.71 USD  5.07%

Максимум 13 USD

Минимум 6 USD

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для Iovance Biotherapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

7 ratings

5

Покупка

2

Удержание

0

Продажа

Настроения

By Acuity

147 / 340Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
help-icon Live chat